about
2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of theReversal of lidocaine effects on sodium currents by isoproterenol in rabbit hearts and heart cells.Electrocardiographic interactions between pinacidil, a potassium channel opener and class I antiarrhythmic agents in guinea-pig isolated perfused heart.Electrophysiological effects of CI-980, a tubulin binding agent, on guinea-pig papillary muscles.Antiarrhythmic drug researchEffects of hyperkalaemia on the depression of maximum rate of depolarization by class I antiarrhythmic agents in guinea-pig myocardium.Electrophysiological effects of CRE-1087 in guinea-pig ventricular muscles.Electrophysiological effects of the combination of mexiletine and flecainide in guinea-pig ventricular fibres.Some recent concepts concerning the mechanisms of action of antiarrhythmic drugs.Classification of antiarrhythmic drugs.Predicting QRS and PR interval prolongations in humans using nonclinical data.Actions of flecainide on susceptibility to phase-2 ventricular arrhythmias during infarct evolution in rat isolated perfused hearts.Role of Sodium Channels in Epilepsy.Role of abnormal repolarization in the mechanism of cardiac arrhythmia.Antiarrhythmic drug classifications and the clinician: a gambit in the land of chaos.Bridging the gap between basic and clinical electrophysiology: what can be learned from monophasic action potential recordings?Classification and mechanism of action of antiarrhythmic drugs.Rate-dependence of class III actions in the heart.Mechanisms of action of antiarrhythmic drugs: from ion channel blockage to arrhythmia termination.Slow kinetic property of mexiletine in guinea pig atrium.Use-dependent effects of pirmenol on Vmax and conduction in guinea-pig ventricular myocardium.Block of single cardiac Na+ channels by antiarrhythmic drugs: the effect of amiodarone, propafenone and diprafenone.Combination of flecainide and mexiletine for the treatment of ventricular tachyarrhythmias.Mode-dependent inhibition by quinidine of Na+-Ca2+ exchanger current from guinea-pig isolated ventricular myocytes.Inhibition of L-type Ca(2+) current in Guinea pig ventricular myocytes by cisapride.Selective depression of maximum rate of depolarization of guinea-pig ventricular action potentials by amiodarone and lignocaine in simulated ischaemia: comparison with encainide.Frequency dependent effects of class I antiarrhythmic agents studied in patients with implanted pacemakers.Comparative haemodynamic effects of verapamil, flecainide, amiodarone and sotalol in the conscious rabbit.Frequency-dependent action of antiarrhythmic drugs: the useful concept of periodical ligand binding.Computational Modeling of Electrophysiology and Pharmacotherapy of Atrial Fibrillation: Recent Advances and Future ChallengesEffects of HIV Protease Inhibitors on Cardiac Conduction Velocity in Unselected HIV-Infected PatientsTime-dependent antiarrhythmic effects of flecainide on induced atrial fibrillation in horses
P2860
Q28087002-FE81FA56-1859-43CC-97FB-7E548F9A90F0Q33891608-1C292EAA-EA50-4C7D-9A04-CCDDC4EF9749Q34793310-95D060AB-A800-48D0-937B-1620E3B90788Q35025380-7AF5FD43-55D2-40EA-A5DB-2B076261AB0DQ35566609-DFC1F4B2-711A-4B7A-B840-B420EC4C1737Q35870956-2C6CF86D-A290-4490-8CD4-62D992DEDF57Q35871199-655D67E1-2F1B-41C0-9D26-E5EE3750975FQ35872072-29E38FD6-B39B-4B68-BBF9-B05E87E9E881Q38195434-697C2C4B-9BDA-4EE9-8807-E114D65E0127Q38651993-EBA28A7E-28C4-4088-B031-81A741B270E1Q38694637-95E101DA-8EAE-4FA0-A27E-EB0E600F20C8Q38756794-C8E59147-783C-4A4D-905F-FBCB959A0259Q38825019-5665AEFE-2B69-48F8-9EAC-A8EDB3A66170Q39434566-CD4995D5-4C38-4ABF-BC2B-B11D10A1EE92Q40388359-8561C6E9-26F1-471B-BC87-EB942FB18584Q40558771-B6F7D871-1D9D-451A-8C39-5D2D74159414Q40604015-7E1D5D8E-56C1-4CAE-BCB2-D24DDA2A9E53Q40889950-70A542CF-F907-4F44-BF40-98ACB51A5B8AQ41372287-EB83DA03-B085-4CD1-AD5D-431DB74674D4Q42035743-8D463FD8-77E4-48F0-AB54-519F671F1B99Q42563625-EB876DAA-0EB4-43CD-A22D-501D854A8B60Q43683887-51D37B18-884E-4841-BAB1-416D23CD8320Q44046333-71AC75B2-0A7C-42BF-B888-3A61FD79D3BCQ44091823-EDEA72BA-9A0E-4E0F-A592-5067633E32BAQ44832401-2A6E97F4-04D6-45ED-9970-084A7036C77BQ46926885-CF52EE19-527A-4763-8DAB-3E031D6CC68FQ51621439-C1CE1984-D04D-4B3C-9A01-41008DDEE8A9Q51639855-F30E434A-3124-48F7-86B8-A9F4D350C218Q53846244-7D1120FF-5091-4721-9D69-E1C50BC6F94FQ57161239-64228CED-9DCE-420F-B110-A55E79F209C3Q57314065-497D3736-C4F3-46BD-BD3C-B09714E1E430Q58716724-0B1D6BAE-E3D0-4A93-90A1-F24539173FBB
P2860
description
1987 nî lūn-bûn
@nan
1987年の論文
@ja
1987年学术文章
@wuu
1987年学术文章
@zh
1987年学术文章
@zh-cn
1987年学术文章
@zh-hans
1987年学术文章
@zh-my
1987年学术文章
@zh-sg
1987年學術文章
@yue
1987年學術文章
@zh-hant
name
Antiarrhythmic agents: modulated receptor applications.
@en
Antiarrhythmic agents: modulated receptor applications.
@nl
type
label
Antiarrhythmic agents: modulated receptor applications.
@en
Antiarrhythmic agents: modulated receptor applications.
@nl
prefLabel
Antiarrhythmic agents: modulated receptor applications.
@en
Antiarrhythmic agents: modulated receptor applications.
@nl
P356
P1433
P1476
Antiarrhythmic agents: modulated receptor applications.
@en
P2093
Hondeghem LM
P304
P356
10.1161/01.CIR.75.3.514
P407
P577
1987-03-01T00:00:00Z